rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TLSA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis - Slideshow

      2026-11-14. The following slide deck was published by Tiziana Life Sciences Ltd in conjunction with this event.

      Nov 14Seeking AlphaTLSA
      Tiziana Life Sciences to advance foralumab partnering talks at BIO-Europe 2026
      Nov 9Yahoo FinanceTLSA
      Tiziana's experimental MS treatment meets main goals in mid-stage study
      Nov 2Yahoo FinanceTLSA
      Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab
      Oct 16Yahoo FinanceTLSA
      Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Intranasal Foralumab in Alzheimer's Disease
      Oct 16Yahoo FinanceTLSA
      Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
      Sep 30Yahoo FinanceTLSA
      Tiziana doses first three patients in ALS trial of nasal antibody foralumab
      Sep 28Yahoo FinanceTLSA
      Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

      Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind,...

      Sep 21Yahoo FinanceTLSA
      Tiziana Life Sciences Signs Saudi Collaboration MOU for New Multiple Sclerosis Trial

      Detailed price information for Tiziana Life Sciences Ltd (TLSA-Q) from The Globe and Mail including charting and trades.

      Sep 18The Globe and MailTLSA
      Tiziana Life Sciences stock jumps on MS trial partnership
      Sep 18Investing.comTLSA
      Why Is Tiziana Life Sciences Stock Gaining Thursday?
      Sep 17BenzingaTLSA
      Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

      Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis...

      Sep 17Yahoo FinanceTLSA
      Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

      Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing...

      Sep 3Yahoo FinanceTLSA
      BTIG initiates Tiziana Life Sciences stock with buy on MS drug
      Sep 3Investing.comTLSA
      Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

      Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch...

      Aug 24Yahoo FinanceTLSA

      This is the newest page. Registered accounts read further back.